Evidence map›Paper›PMID 24401748›Full record

ArticleCell cycle (Georgetown, Tex.)2014

miR-34a is essential for p19(Arf)-driven cell cycle arrest.

Nida Iqbal, Jie Mei, Jing Liu, Stephen X Skapek

Open access · bronzeAbstract read
In one paragraph

Article in Cell cycle (Georgetown, Tex.), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.3field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 17 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Mir-34: a new weapon against cancer?Molecular therapy. Nucleic acids · 2014
    Review
  14. Article
  15. Article
  16. ARF sees Pdgfrβ through the miR.Cell cycle (Georgetown, Tex.) · 2014
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 2 countries.

Nida IqbalDivision of Hematology/Oncology; Department of Pediatrics; University of Texas Southwestern Medical Center; Dallas, TX USA.
Jie MeiDivision of Hematology/Oncology; Department of Pediatrics; University of Texas Southwestern Medical Center; Dallas, TX USA; College of Fisheries; Key Laboratory of Freshwater Animal Breeding; Ministry of Agriculture; Huazhong Agricultural University; Wuhan, China.
Jing LiuDivision of Hematology/Oncology; Department of Pediatrics; University of Texas Southwestern Medical Center; Dallas, TX USA.
Stephen X SkapekDivision of Hematology/Oncology; Department of Pediatrics; University of Texas Southwestern Medical Center; Dallas, TX USA; Center for Cancer and Blood Disorders; Children's Medical Center; Dallas, TX USA.
Southwestern Medical CenterHuazhong Agricultural University · CNThe University of Texas Southwestern Medical Center · US

Funding

ARF Controls Vascular Regression During Eye DevelopmentR01EY014368 · NEI · UT SOUTHWESTERN MEDICAL CENTER · PI SKAPEK, STEPHEN X · 2003 to 2012
$3.4M
Tgf Beta 2 controls p19Arf During Eye DevelopmentR01EY019942 · NEI · UT SOUTHWESTERN MEDICAL CENTER · PI SKAPEK, STEPHEN X · 2010 to 2017
$2.6M
NEI NIH HHS EY 014368NEI NIH HHS EY 019942NEI NIH HHS R01 EY014368NEI NIH HHS R01 EY019942
6 · The paper itself

Abstract

The Arf tumor suppressor gene product, p19(Arf), regulates cell proliferation in incipient cancer cells and during embryo development. Beyond its commonly accepted p53-dependent actions, p19(Arf) also acts independently of p53 in both contexts. One such p53-independent effect with in vivo relevance includes its repression of Pdgfrβ, a process that is essential for vision in the mouse. We have utilized cell culture-based and mouse models to define a new role for miR-34a in this process. Ectopic expression of Arf in cultured cells enhanced the expression of several microRNAs predicted to target Pdgfrß synthesis, including the miR-34 family. Because miR-34a has been implicated as a p53-dependent effector, we investigated whether it also contributed to p53-independent effects of p19(Arf). Indeed, in mouse embryo fibroblasts (MEFs) lacking p53, Arf-driven repression of Pdgfrβ and its blockade of Pdgf-B stimulated DNA synthesis were both completely interrupted by anti-microRNA against miR-34a. Ectopic miR-34a directly targeted Pdgfrβ and a plasmid reporter containing wild-type Pdgfrβ 3'UTR sequence, but not one in which the miR-34a target sequence was mutated. Although miR-34a expression has been linked to p53-a well-known effector of p19(Arf)-Arf expression and its knockdown correlated with miR-34a level in MEFs lacking p53. Finally, analysis of the mouse embryonic eye demonstrated that Arf controlled expression of miR-34a, and the related miR-34b and c, in vivo during normal mouse development. Our findings indicate that miR-34a provides an essential link between p19(Arf) and its p53-independent capacity to block cell proliferation driven by Pdgfrβ. This has ramifications for developmental and tumor suppressor roles of Arf.

Indexed as

AnimalsCell Cycle CheckpointsCell LineCell ProliferationCyclin-Dependent Kinase Inhibitor p16EyeMice, 129 StrainMice, Inbred C57BLMicroRNAsReceptor, Platelet-Derived Growth Factor betaTumor Suppressor Protein p53Cdkn2a protein, mouseCyclin-Dependent Kinase Inhibitor p16MicroRNAsMIRN34a microRNA, mouseReceptor, Platelet-Derived Growth Factor betaTumor Suppressor Protein p53cell cyclemiR-34ap19Arfp53Pdgfrβtumor suppressionvascular remodeling

Identifiers

PMID24401748
PMCPMC3979915
OpenAlexW1973668208

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.